Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table-Reference-Cited by-同舟云学术

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

Published:2024-07 Issue: Volume: Page:
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Mach François^ORCID,Visseren Frank L.J.,Cater Nilo B.,Salhi Nejoua,Soronen Jarkko,Ray Kausik K.^ORCID,Delgado Victoria^ORCID,Jukema J. Wouter,Laufs Ulrich^ORCID,Zamorano Jose-Luis,Ros Emilio^ORCID,Plat Jogchum,Gesztes Akos Gabor,Tokgozoglu Lale,Packard Chris,Libby Peter

Publisher

Elsevier BV

Reference133 articles.

1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study;Lancet,2019

2. Epidemiology of cardiovascular disease in Europe;Townsend;Nat Rev Cardiol,2022

3. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019;Lancet,2020

4. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017

5. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potentials of peptide-derived nanoformulations in atherosclerosis: present status and future directions;International Journal of Smart and Nano Materials;2024-07-02